Newborn Screening Quality Assurance Program, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, Mail Stop F-19, Atlanta, GA 30341, USA.
Clin Chim Acta. 2010 May 2;411(9-10):684-9. doi: 10.1016/j.cca.2010.01.034. Epub 2010 Feb 1.
The analysis of amino acids (AA) and acylcarnitines (AC) by tandem mass spectrometry (MS/MS) is performed in newborn screening laboratories worldwide. While butyl esterification assays are routine, it is possible to detect AAs and ACs as their native free acids (underivatized). The Centers for Disease Control and Prevention's Newborn Screening Quality Assurance Program provides dried blood spot (DBS) quality control (QC) and proficiency testing (PT) programs for numerous MS/MS analytes. We describe empirical differences between derivatization and non-derivatization techniques for selected AAs and ACs.
DBS materials were prepared at levels near, above and below mean domestic laboratory cut-offs, and distributed to program participants for MS/MS analysis. Laboratories reported quantitative and qualitative results. QC DBS materials were assayed in-house following established protocols.
Minor differences (<15%) between quantitative values resulting from butyl esters and free acid techniques were observed for the majority of the analytes. Mass spectrometric response from underivatized dicarboxylic acid acylcarnitines was less intense than their butyl esters.
The use of underivatized techniques may also result in the inability to differentiate isobaric acylcarnitines. Laboratories should establish their own protocols by focusing on the decisions that identify test results requiring additional follow-up testing versus those that do not.
串联质谱(MS/MS)分析氨基酸(AA)和酰基肉碱(AC)已在全球新生儿筛查实验室中进行。虽然丁酯化分析是常规方法,但也可以检测到未衍生的天然游离酸形式的 AA 和 AC。疾病控制和预防中心的新生儿筛查质量保证计划为许多 MS/MS 分析物提供了干血斑(DBS)质量控制(QC)和能力验证(PT)计划。我们描述了选定 AA 和 AC 的衍生化和非衍生化技术之间的经验差异。
在接近、高于和低于国内实验室常规截止值的水平下制备 DBS 材料,并分发给计划参与者进行 MS/MS 分析。实验室报告定量和定性结果。根据既定方案,在内部检测 QC DBS 材料。
对于大多数分析物,丁酯和游离酸技术的定量值之间存在较小差异(<15%)。未衍生的二羧酸酰基肉碱的质谱响应强度低于其丁酯。
使用未衍生的技术也可能导致无法区分等电酰基肉碱。实验室应通过关注确定需要进一步随访测试的测试结果与无需进一步随访测试的测试结果的决策来建立自己的方案。